To further isolate the effects of sorafenib and CTNNB1 in a controlled setting with clearer genetic backgrounds, we examined drug sensitivity data (52) and CRISPR knockout screening results among liver cancer cell lines from Cancer Dependency Map (DepMap; Supplementary Methods; ref. 53). This evidence concerns the gene CTNNB1 and liver cancer.